News | March 21, 2007

St Jude Receives FDA Clearance for First U.S. CRT Device with A-Fib Feature

March 22, 2007 — St. Jude Medical Inc. says it has received FDA approval of a new cardiac rhythm management device designed to help physicians manage heart failure (HF) patients, including patients who have or may develop atrial fibrillation (AF).

The Atlas II HF CRT-D (cardiac resynchronization therapy defibrillator) is the first U.S. heart failure device to offer the AF Suppression proprietary algorithm that helps maintain control of the heart's atrial rhythm by pacing slightly faster than the patient's natural heart rate. The AF Suppression algorithm has been clinically proven to reduce the AF burden (the percentage of days
with AF symptoms) in previous studies.

"The AF Suppression algorithm provides me with an effective non-pharmacological method for treating my heart failure patients who have AF," said Steven Greenberg, M.D., of the Cardiac Arrhythmia and Pacemaker Center, in Roslyn, N.Y. "With this novel device, I can treat heart failure, while suppressing AF."

Atlas II HF CRT-D also offers the company's QuickOpt timing cycle optimization feature, a programmer-based optimization for people with CRT-D devices and traditional ICDs that helps physicians quickly program the device's timing so it delivers optimal therapy to patients.

Other features of the Atlas II HF CRT-D are designed to help physicians manage difficult-to-treat conditions:

• DeFT Response technology and unsurpassed energy output (36 J delivered energy, 42 J stored energy) help physicians manage the unpredictably high defibrillation thresholds that affect as many as
one in eight heart failure patients.

• Remote monitoring enables device information to be downloaded and accessed from any computer with Internet access, enabling routine follow-up to be conducted from the convenience of the patient's home.

Related Content

Medtronic AdaptivCRT Feature Associated with Improved Heart Failure Patient Survival
News | Cardiac Resynchronization Therapy Devices (CRT) | May 22, 2018
Medtronic plc announced study results showing its AdaptivCRT algorithm is associated with improved patient survival....
Medtronic Recalls CRT-Ds and ICDs Due to Manufacturing Error Preventing Electrical Shock Delivery
News | Cardiac Resynchronization Therapy Devices (CRT) | February 26, 2018
The U.S. Food and Drug Administration (FDA) announced that Medtronic is recalling certain implantable cardioverter...
Abbott Announces MR-Conditional Labeling for Quadra Assura CRT-D and Fortify Assura ICD
Technology | Cardiac Resynchronization Therapy Devices (CRT) | January 03, 2018
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT) | August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT) | July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Videos | Cardiac Resynchronization Therapy Devices (CRT) | May 23, 2017
This video, provided by ERB, demonstrates the function and implantation of the WiSE CRT (Wireless Stimulation Endocar
Biotronik Announces FDA Approval of MultiPole Pacing
Technology | Cardiac Resynchronization Therapy Devices (CRT) | May 11, 2017
May 11, 2017 — Biotronik announced U.S.
Biotronik Launches First FDA-Approved CRM Devices with MRI AutoDetect Technology
Technology | Cardiac Resynchronization Therapy Devices (CRT) | May 10, 2017
Biotronik announced the availability of the first U.S. Food and Drug Administration (FDA)-approved cardiac rhythm...
Overlay Init